SCHEMBL18558256

SCHEMBL18558256

CC(C)(C)N/C(=N/C(=O)c1cccc(C#N)c1)Nc1cc(-c2ccc(F)cc2)n[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VNN1 O95497 2/20 0.39
HDAC2 Q92769 2/20 0.38
PPARG P37231 1/20 0.37
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
MAPK1 P28482 2/20 0.35
CA12 O43570 1/20 0.35
ALPL P05186 1/20 0.35
RPA1 P27694 1/20 0.35
GRM5 P41594 2/20 0.35
MAPK14 Q16539 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TBXA2R P21731 2/20 0.34
PRKAA2 P54646 1/20 0.34
CDC7 O00311 1/20 0.34
DAPK3 O43293 1/20 0.34
ROCK2 O75116 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18558455 0.93 VNN1 (0.35) VNN1MAPK1GRM5
SCHEMBL18558203 0.92 VNN1 (0.39) VNN1CA12ALPLGRM5TBXA2R
SCHEMBL18558515 0.90 VNN1 (0.38) VNN1HDAC2PPARGMAPK1KDM4E
SCHEMBL18558233 0.90 MAPK1 (0.38) VNN1HDAC2PPARGMAPK1CA12
SCHEMBL18558486 0.89 NPC1 (0.40) HDAC2CA12ALPLRPA1KDM4E
SCHEMBL18558565 0.89 VNN1 (0.39) VNN1HDAC2PPARGGABRG2GABRB3
SCHEMBL18558028 0.88 VNN1 (0.39) VNN1HDAC2PPARGGABRG2GABRB3
SCHEMBL18557846 0.87 VNN1 (0.36) VNN1HDAC2PPARGMAPK1KDM4E
SCHEMBL18558653 0.87 IDO1 (0.39) VNN1HDAC2CA12ALPLRPA1
SCHEMBL18558410 0.87 CA12 (0.37) HDAC2CA12ALPLRPA1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9932313-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2018-04-03 US disclosed
US-20170267643-A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-09-21 US disclosed
US-9580388-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2017-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267643-A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF ATP5F1A, ATP5F1D, ATP5ME VNN1 2342/4885HDAC2 2125/4885PPARG 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.